The Role of GLP-1 Medications in Your Weight Loss Journey

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Every FDA-approved GLP-1 weight-management label uses the same phrase, and it is the most important sentence in the whole document: the medication is indicated in combination with a reduced-calorie diet and increased physical activity. That is not a disclaimer bolted on for legal cover. It describes the conditions under which the drug was studied, and therefore the only conditions under which its published results apply. The role of a GLP-1 medication in a weight-loss effort is to make a sustained calorie deficit biologically achievable for people for whom it previously was not — not to replace the deficit.

What "Adjunct" Means in Practice

In the pivotal trials, participants did not simply receive an injection and go home. In the Zepbound weight-reduction program, patients received instruction on a reduced-calorie diet of roughly a 500 kcal/day deficit and physical activity counseling with a recommended minimum of 150 minutes per week, beginning with the first dose and continuing throughout, plus counseling on behavior modification strategies. The placebo groups received the same instruction. The published differences between arms are therefore differences on top of a structured lifestyle intervention.

This is why the honest framing is a partnership rather than a substitution. The medication changes appetite signaling and how full you feel; the diet, the protein intake, the activity and the sleep still determine a great deal of the outcome, and they determine almost all of what happens to body composition rather than body weight alone.

What the Trials Actually Produced

The magnitude is genuinely large by the standards of previous obesity pharmacotherapy. In the Zepbound label's Study 1, a 72-week trial in 2,539 adults with obesity or overweight plus a weight-related condition and without type 2 diabetes, mean weight change from baseline was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg dosages, versus −3.1% with placebo. In the same study, 85.1%, 88.9% and 90.9% of treated patients lost at least 5% of body weight, compared with 34.5% on placebo.

For semaglutide, the corresponding 68-week weight-management trial reported roughly a −14.9% mean change versus −2.4% with placebo. The Wegovy label now also includes a higher-dose arm: in the study supporting the 7.2 mg once-weekly dosage, 72 weeks of treatment in 1,407 adults produced mean changes of −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9% with placebo.

The Part People Skip: What Happens When Treatment Stops

Two withdrawal trials answer this directly, and both point the same way. In STEP 4, 803 adults who had already lost a mean of 10.6% during a 20-week run-in were randomized either to continue semaglutide 2.4 mg or to switch to placebo. Over the following 48 weeks, the continued-treatment group lost a further 7.9% while the placebo group regained 6.9% — a 14.8 percentage-point difference.

The tirzepatide equivalent is Study 4 in the Zepbound label, an 88-week randomized withdrawal trial. Patients lost an average of 20.9% during a 36-week open-label lead-in, at which point mean body weight had fallen from 107.3 kg to 85.2 kg. They were then randomized to continue or to switch to placebo for 52 weeks, and the group that stopped regained weight. Obesity behaves like a chronic condition in these datasets, and the medication behaves like a chronic treatment.

Benefits That Are Not Measured on the Scale

Some of the strongest evidence in this class is not about weight at all. In SELECT, 17,604 adults aged 45 or older with pre-existing cardiovascular disease and a BMI of 27 or greater but without diabetes were randomized to semaglutide 2.4 mg or placebo. A primary cardiovascular endpoint event occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a hazard ratio of 0.80 over a mean follow-up of just under 40 months.

Function matters too. In STEP-HFpEF, 529 patients with heart failure with preserved ejection fraction and a BMI of 30 or higher received semaglutide 2.4 mg or placebo for 52 weeks; the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score was 16.6 points with semaglutide versus 8.7 with placebo, and the 6-minute walk distance improved by 21.5 m versus 1.2 m. These are the findings that drove Wegovy's cardiovascular indication and, separately, its liver indication.

The Costs the Brochures Underplay

Gastrointestinal effects are the dominant tolerability issue across the class. The most common adverse reactions in the Wegovy label, reported at 5% or more, include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroesophageal reflux disease and hair loss. Severe gastrointestinal reactions were reported in 4.1% of Wegovy injection patients versus 0.9% on placebo in the adult weight-reduction trials.

There are also warnings that require monitoring rather than reassurance: acute pancreatitis, gallbladder disease with a specific note that rapid weight loss itself raises the risk of cholelithiasis, acute kidney injury following dehydration from vomiting or diarrhea, resting heart rate increases, and rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation. None of these are reasons not to treat; all of them are reasons the treatment belongs inside a clinical relationship.

What Stays Yours

Appetite suppression creates a window, and what you put into that window is what you keep. Reduced intake without adequate protein and resistance training tends to cost lean mass alongside fat mass, which is a poor trade for long-term metabolic health. Sleep, alcohol, stress and activity all continue to influence the result, and none of them is affected by the injection.

The medication also cannot tell you when it is working badly. That judgment — whether side effects are acceptable, whether progress is reasonable, whether something else is going on — requires a clinician following you over time. The role of a GLP-1 in a weight-loss journey is best understood as one instrument in a longer clinical relationship, not the whole of it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do GLP-1 medications work without diet and exercise changes?

The approved labels all specify use in combination with a reduced-calorie diet and increased physical activity, and that is how the trials were run. In the Zepbound weight-reduction studies, all participants including the placebo group received instruction on roughly a 500 kcal/day deficit and at least 150 minutes of activity per week. The published results describe what the medication added on top of that structure, not what it does in isolation.

How much weight did people lose in the pivotal trials?

In the Zepbound label's 72-week Study 1 in 2,539 adults without diabetes, mean weight change was −15.0%, −19.5% and −20.9% at 5 mg, 10 mg and 15 mg versus −3.1% with placebo. For semaglutide, the 68-week weight-management trial reported approximately −14.9% versus −2.4%, and the study supporting Wegovy's 7.2 mg dosage reported −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9% over 72 weeks.

What happens to weight if you stop a GLP-1 medication?

Both withdrawal trials show regain. In STEP 4, adults who had lost a mean of 10.6% during a 20-week run-in and then switched to placebo regained 6.9% over the next 48 weeks, while those who continued semaglutide lost a further 7.9%. In the Zepbound label's Study 4, patients lost an average of 20.9% over a 36-week open-label period and the group randomized to placebo afterward regained weight over the following 52 weeks.

Do these medications do anything besides reduce weight?

Yes, and some of the evidence is on hard outcomes. In SELECT, involving 17,604 adults with established cardiovascular disease and a BMI of 27 or greater without diabetes, the primary cardiovascular endpoint occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo. In STEP-HFpEF, 529 patients with heart failure with preserved ejection fraction and obesity saw larger symptom-score and walk-distance improvements on semaglutide than on placebo over 52 weeks.

What are the most common side effects to expect?

Gastrointestinal effects dominate. The Wegovy label lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, reflux and hair loss among reactions occurring in at least 5% of patients. Severe gastrointestinal reactions were reported in 4.1% of Wegovy injection patients versus 0.9% on placebo. Discuss tolerability and any persistent severe abdominal pain with your prescriber promptly.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.